Alfonso R. Sánchez-Paulete
YOU?
Author Swipe
View article: Critical Evaluation of Synthetic High-density Lipoproteins for Thrombosis Applications: Insights into the Antiplatelet Interactions and Mechanisms
Critical Evaluation of Synthetic High-density Lipoproteins for Thrombosis Applications: Insights into the Antiplatelet Interactions and Mechanisms Open
High-density lipoproteins (HDLs) are renowned for their cardioprotective properties, including anti-inflammatory, antioxidant, antiapoptotic, and antithrombotic activities. Given this wide range of protective functions, numerous synthetic …
View article: TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer Open
View article: Supplementary Table from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Supplementary Table from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity Open
Supplementary Table from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
View article: Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity Open
Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
View article: Supplementary Table from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Supplementary Table from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity Open
Supplementary Table from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
View article: Data from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Data from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity Open
Tumor-associated macrophages (TAM) are one of the most abundant cell types in many solid tumors and typically exert protumor effects. This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed t…
View article: Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity Open
Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
View article: Data from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Data from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity Open
Tumor-associated macrophages (TAM) are one of the most abundant cell types in many solid tumors and typically exert protumor effects. This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed t…
View article: Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
Primer sequences
View article: Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with urelumab
View article: Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Supplementary Figure Legends
View article: Supplementary Figure 3 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 3 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Systemic sFlt3L and local intratumoral poly-ICLC expand and mature DCs in B16-OVA bearing mice.
View article: Supplemental Figures 1-10 from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Supplemental Figures 1-10 from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation Open
Figure S1 shows that CD8 T cells with high mitochondrial transmembrane potential after CD137 stimulation have enlarged mitochondria. Fig S2 shows that CD137 induced mitochondrial changes are not due to enrichment of specific CD8 T cells su…
View article: Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Supplementary Figure Legends
View article: Supplementary Figure 4 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 4 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Combinations of immunomodulatory anti-CD137 and anti-PD-1 mAbs synergize with sFlt3L and poly-ICLC against grafted B16F10 and B16-OVA melanomas.
View article: Data from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Data from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade Open
Virotherapy and checkpoint inhibitors can be combined for the treatment of cancer with complementarity and potential for synergistic effects. We have developed a cytolytic but nonreplicative viral vector system based on Semliki Forest viru…
View article: Supplementary Figure 2 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 2 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
CTLs against the Adpgk neoantigen of MC38 are induced by anti-CD137 and anti-PD-1 mAbs in a fraction of WT mice, but not in Batf3-/- mice.
View article: Data from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Data from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Weak and ineffective antitumor cytotoxic T lymphocyte (CTL) responses can be rescued by immunomodulatory mAbs targeting PD-1 or CD137. Using Batf3−/− mice, which are defective for cross-presentation of cell-associated ant…
View article: Supplementary Figure 1 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 1 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Migratory CD103+ DCs are the main mediators of cross-priming at the tumor-draining LNs.
View article: supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
No change in memory naive proportions and their DNA methylation in relevant genes
View article: Data from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Data from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation Open
T and NK lymphocytes express CD137 (4-1BB), a costimulatory receptor of the TNFR family whose function is exploitable for cancer immunotherapy. Mitochondria regulate the function and survival of T lymphocytes. Herein, we show that CD137 co…
View article: Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with 6B4 antiCD137 mAb
View article: Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with urelumab
View article: supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
No change in memory naive proportions and their DNA methylation in relevant genes
View article: Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade Open
Supplementary figure 1. Similar survival results with anti-PD-1 or anti-PD-L1 in the combination with SFV-IL12 for B16-OVA-derived tumors.
View article: Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with 6B4 antiCD137 mAb
View article: Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
Primer sequences
View article: Supplementary Figure 4 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 4 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Combinations of immunomodulatory anti-CD137 and anti-PD-1 mAbs synergize with sFlt3L and poly-ICLC against grafted B16F10 and B16-OVA melanomas.
View article: Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade Open
Supplementary figure 1. Similar survival results with anti-PD-1 or anti-PD-L1 in the combination with SFV-IL12 for B16-OVA-derived tumors.
View article: Supplementary Figure Legends from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Supplementary Figure Legends from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade Open
Supplementary figure legends